MCID: MLT006
MIFTS: 47

Multidrug-Resistant Tuberculosis

Categories: Infectious diseases

Aliases & Classifications for Multidrug-Resistant Tuberculosis

MalaCards integrated aliases for Multidrug-Resistant Tuberculosis:

Name: Multidrug-Resistant Tuberculosis 12 15
Tuberculosis, Multidrug-Resistant 44 73
Tuberculosis Multidrug-Resistant 55

Classifications:



External Ids:

Disease Ontology 12 DOID:401
MeSH 44 D018088
SNOMED-CT 68 423092005
UMLS 73 C0206526

Summaries for Multidrug-Resistant Tuberculosis

Disease Ontology : 12 A tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs.

MalaCards based summary : Multidrug-Resistant Tuberculosis, also known as tuberculosis, multidrug-resistant, is related to lymphadenitis and pulmonary tuberculosis. An important gene associated with Multidrug-Resistant Tuberculosis is INHA (Inhibin Subunit Alpha), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Sirturo and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are digestive/alimentary and neoplasm

Wikipedia : 76 Multi-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria... more...

Related Diseases for Multidrug-Resistant Tuberculosis

Diseases related to Multidrug-Resistant Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 lymphadenitis 30.6 IL10 SLC11A1 TNF
2 pulmonary tuberculosis 29.8 IL10 INHA SLC11A1 TNF VDR
3 punctate inner choroidopathy 10.8 IL10 TNF
4 tropical endomyocardial fibrosis 10.8 IL10 TNF
5 microscopic polyangiitis 10.8 IL10 TNF
6 multifocal choroiditis 10.8 IL10 TNF
7 tungiasis 10.8 IL10 TNF
8 endomyocardial fibrosis 10.8 IL10 TNF
9 transient hypogammaglobulinemia 10.8 IL10 TNF
10 choroiditis 10.8 IL10 TNF
11 idiopathic achalasia 10.8 IL10 TNF
12 trichuriasis 10.7 IL10 TNF
13 mucocutaneous leishmaniasis 10.7 IL10 TNF
14 clonorchiasis 10.7 IL10 TNF
15 adult dermatomyositis 10.7 TNF VDR
16 trachoma 10.7 IL10 TNF
17 nontuberculous mycobacterial lung disease 10.7 SLC11A1 TNF
18 listeriosis 10.7 IL10 TNF
19 transverse myelitis 10.7 IL10 TNF
20 buruli ulcer 10.7 IL10 SLC11A1
21 primary systemic mycosis 10.7 IL10 TNF
22 poliomyelitis 10.6 IL10 TNF
23 campylobacteriosis 10.6 SLC11A1 VDR
24 intermediate uveitis 10.6 IL10 TNF
25 orofacial granulomatosis 10.6 IL10 TNF
26 coccidiosis 10.6 IL10 TNF
27 skin conditions 10.6 IL1A TNF
28 scabies 10.6 IL10 IL1A
29 hand, foot and mouth disease 10.6 IL10 VDR
30 west nile fever 10.6 DEFA1 DEFA3
31 eales disease 10.5 IL10 TNF
32 irritant dermatitis 10.5 IL1A TNF
33 mite infestation 10.5 DEFA1 DEFA3
34 hemorrhagic fever 10.5 IL10 TNF
35 chronic graft versus host disease 10.5 IL10 IL1A
36 stachybotrys chartarum 10.5 IL1A TNF
37 bell's palsy 10.5 DEFA1 DEFA3
38 spotted fever 10.5 IL10 TNF
39 hematopoietic stem cell transplantation 10.5 IL10 TNF
40 brucellosis 10.5 IL10 SLC11A1 TNF
41 leprosy 3 10.4 IL10 SLC11A1 TNF
42 cutaneous leishmaniasis 10.4 IL10 SLC11A1 TNF
43 lepromatous leprosy 10.4 IL10 TNF VDR
44 soft tissue sarcoma 10.4 ABCB1 TNF
45 prostatitis 10.4 IL10 TNF VDR
46 visceral leishmaniasis 10.4 IL10 SLC11A1 TNF
47 microsporidiosis 10.4 ABCB1 DEFA1
48 mouth disease 10.4 IL10 TNF VDR
49 multicentric castleman disease 10.4 ABCB1 IL10
50 panuveitis 10.4 IL10 TNF

Graphical network of the top 20 diseases related to Multidrug-Resistant Tuberculosis:



Diseases related to Multidrug-Resistant Tuberculosis

Symptoms & Phenotypes for Multidrug-Resistant Tuberculosis

MGI Mouse Phenotypes related to Multidrug-Resistant Tuberculosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 IL10 INHA SLC11A1 TNF VDR ABCB1
2 neoplasm MP:0002006 9.02 IL10 IL1A INHA SLC11A1 TNF

Drugs & Therapeutics for Multidrug-Resistant Tuberculosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Sirturo 18 BEDAQUILINE FUMARATE Janssen Therapeutics December 2012

Drugs for Multidrug-Resistant Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 100986-85-4 149096
2
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Not Applicable 82419-36-1 4583
3
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
4
Linezolid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 165800-03-3 441401
5
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
6
Amikacin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 37517-28-5 37768
7
Capreomycin Approved Phase 4,Not Applicable 11003-38-6 3000502
8
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2030-63-9 2794
9
Ethambutol Approved Phase 4,Phase 3,Phase 2,Not Applicable 74-55-5 3279 14052
10
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
11
Prothionamide Approved, Investigational Phase 4,Phase 3,Phase 2 14222-60-7 666418
12
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-96-4 1046
13
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
14
Aminosalicylic Acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 65-49-6 4649
15
Bedaquiline Approved Phase 4,Phase 3,Phase 2,Phase 1 843663-66-1
16
Cycloserine Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-41-7 401 6234
17
Ethionamide Approved Phase 4,Phase 2,Phase 3,Not Applicable 536-33-4 2761171
18
Kanamycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 8063-07-8, 59-01-8 6032
19
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 57-92-1 19649
20
Amoxicillin Approved, Vet_approved Phase 4,Phase 2 26787-78-0 33613
21
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 447043
22
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
23
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
24
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
25
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
26
Rifabutin Approved, Investigational Phase 4,Phase 2,Not Applicable 72559-06-9 6323490
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
31 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 2
40 beta-Lactamase Inhibitors Phase 4
41 Clavulanic Acid Phase 4,Phase 2
42 Thioacetazone Phase 4
43
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
44 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
45
Ethinyl Estradiol Approved Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
46
Norgestimate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 35189-28-7 6540478
47
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
48
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
49
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
50 Antiviral Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
2 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
3 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
4 The Individualized M(X) Drug-resistant TB Treatment Strategy Study Recruiting NCT03237182 Phase 4 Individualized TB treatment with multiple drugs;Standardized TB treatment with multiple drugs
5 Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide Unknown status NCT02120638 Phase 3 Pyrazinamide containing regimen;Regimen without Pyrazinamide
6 Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis Completed NCT01424670 Phase 3 Delamanid;Placebo;Optimized Background Regimen (OBR);Antiretrovirals (ARVs)
7 High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
8 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
9 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3
10 Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB Recruiting NCT03069534 Phase 2, Phase 3 RhIL-2
11 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen;Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline
12 An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Recruiting NCT02454205 Phase 2, Phase 3 Linezolid;Bedaquiline;Levofloxacin;Pyrazinamide;Isoniazid;Ethionamide;Terizidone;Moxifloxacin;Kanamycin
13 Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
14 Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
15 Evaluating Newly Approved Drugs for Multidrug-resistant TB Recruiting NCT02754765 Phase 3 Bedaquiline;Delamanid;Clofazimine;Levofloxacin;Moxifloxacin;Linezolid;Pyrazinamide
16 FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis Recruiting NCT02607449 Phase 3 FS-1;Placebo
17 A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis Active, not recruiting NCT02333799 Phase 3 Bedaquiline;PA-824;Linezolid
18 Shortening Treatment by Advancing Novel Drugs Active, not recruiting NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol combination tablet);HR (rifampicin plus isoniazid combination tablets)
19 TB Immunotherapy Trial With Heat-killed M. Vaccae Enrolling by invitation NCT01977768 Phase 3
20 Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients Not yet recruiting NCT03568383 Phase 3 Delamanid (DLM);Isoniazid (INH)
21 Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients Terminated NCT01055145 Phase 3 levofloxacin, moxifloxacin
22 A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis Withdrawn NCT01600963 Phase 3 Arm A Double-blind Phase: TMC207;Arm B Double-blind Phase: Placebo;Treatment Failure During Double-blind Phase: TMC207;Treatment Failure During Follow-up Phase: TMC207
23 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
24 Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis Unknown status NCT01994460 Phase 2 Linezolid;Ethambutol
25 To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. Completed NCT00910871 Phase 2 TMC207;Background Regimen (BR) for MDR-TB
26 TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Completed NCT00664313 Phase 1, Phase 2 Linezolid;Placebo
27 TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). Completed NCT00449644 Phase 2 TMC207;Placebo;Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
28 A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Completed NCT00685360 Phase 2 OPC-67683;OPC-67683;Placebo
29 Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB) Completed NCT00691392 Phase 1, Phase 2 Linezolid;Microcrystalline Methylcellulose - Placebo
30 Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis Completed NCT01131351 Phase 2 OPC-67683
31 A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Completed NCT02573350 Phase 2 Delamanid
32 Metronidazole for Pulmonary Tuberculosis (South Korea) Completed NCT00425113 Phase 2 Metronidazole
33 Linezolid to Treat Extensively-Drug Resistant Tuberculosis Completed NCT00727844 Phase 2 Immediate Start Linezolid;Delayed Start Linezolid
34 Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients Completed NCT01222338 Phase 2
35 A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. Completed NCT02193776 Phase 2 Pa-824;bedaquiline;moxifloxacin;pyrazinamide;isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
36 Interferon Gamma for Drug Resistant Tuberculosis Completed NCT00001407 Phase 2 Interferon Gamma
37 Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB Recruiting NCT02354014 Phase 2 Bedaquiline (TMC207);Background Regimen (BR)
38 Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB Recruiting NCT03141060 Phase 1, Phase 2 Delamanid;Optimized multidrug background regimen (OBR) for children with MDR-TB
39 Treatment Shortening of MDR-TB Using Existing and New Drugs Recruiting NCT02619994 Phase 2 Linezolid;Delamanid;Levofloxacin;Pyrazinamide;Locally-used WHO-approved MDR-TB regimen in Korea
40 Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis Recruiting NCT02906007 Phase 1, Phase 2 Bedaquiline
41 Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis Recruiting NCT02583048 Phase 2 Bedaquiline;Delamanid;Dolutegravir
42 Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis Recruiting NCT03160638 Phase 2 Azithromycin 250 mg
43 Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly Recruiting NCT02415985 Phase 2 Lopinavir/r will be supplied by NHSO/GPO;Rifabutin
44 An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) Active, not recruiting NCT02365623 Phase 2 TMC207 (bedaquiline);Background Regimen (BR)
45 A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis Active, not recruiting NCT01859923 Phase 2 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
46 Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Active, not recruiting NCT01918397 Phase 2 Levofloxacin;Optimized background regimen (OBR)
47 Safety of RUTI® Vaccination in MDR-TB Patients Not yet recruiting NCT02711735 Phase 2
48 Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Not yet recruiting NCT03338621 Phase 2 Pretomanid;Bedaquiline;Moxifloxacin;Pyrazinamide;HRZE;HR
49 Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis Completed NCT01856634 Phase 1 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
50 Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin

Search NIH Clinical Center for Multidrug-Resistant Tuberculosis

Cochrane evidence based reviews: tuberculosis, multidrug-resistant

Genetic Tests for Multidrug-Resistant Tuberculosis

Anatomical Context for Multidrug-Resistant Tuberculosis

MalaCards organs/tissues related to Multidrug-Resistant Tuberculosis:

41
Testes, Lung, T Cells, Whole Blood, Bone, B Cells, Neutrophil

Publications for Multidrug-Resistant Tuberculosis

Articles related to Multidrug-Resistant Tuberculosis:

(show top 50) (show all 680)
# Title Authors Year
1
Genome sequence of Mycobacterium yongonense RT 955-2015 isolate from a patient misdiagnosed with multidrug-resistant tuberculosis: First clinical detection in Tanzania. ( 29702266 )
2018
2
Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. ( 29297422 )
2018
3
Multidrug-resistant Tuberculosis Lymphadenitis as the Initial Presentation of Secondary Multidrug-resistant Tuberculosis: A Case Report. ( 29805932 )
2018
4
Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China. ( 29437632 )
2018
5
Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment. ( 29319026 )
2018
6
Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. ( 29944658 )
2018
7
Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. ( 29416359 )
2018
8
Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa. ( 29297424 )
2018
9
Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study. ( 29970076 )
2018
10
Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. ( 29319042 )
2018
11
Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study. ( 29914603 )
2018
12
Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. ( 29855354 )
2018
13
Diagnostic accuracy and utility of a new molecular assay for multidrug-resistant tuberculosis: FluoroType MTBDR. ( 29976588 )
2018
14
Treatment of Multidrug-Resistant Tuberculosis Infection in Children. ( 29742640 )
2018
15
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis. ( 29280429 )
2018
16
The use of whole-genome sequencing inA cluster investigation of a multidrug-resistant tuberculosis outbreak. ( 29748309 )
2018
17
Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. ( 29788331 )
2018
18
Multidrug-Resistant Tuberculosis in the End Tuberculosis EraMultidrug-Resistant Tuberculosis in the End Tuberculosis Era. ( 29924256 )
2018
19
Sequelae of multidrug-resistant tuberculosis: protocol for a systematic review and meta-analysis. ( 29440162 )
2018
20
Have compensatory mutations facilitated the current epidemic of multidrug-resistant tuberculosis? ( 29872078 )
2018
21
Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area. ( 29887187 )
2018
22
Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. ( 29348152 )
2018
23
Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis. ( 29791488 )
2018
24
Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. ( 29297426 )
2018
25
Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. ( 29280409 )
2018
26
Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert<sup>Ar</sup> MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis. ( 29862440 )
2018
27
Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up. ( 29394358 )
2018
28
Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis. ( 29791559 )
2018
29
Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. ( 29942536 )
2018
30
Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. ( 29374587 )
2018
31
Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. ( 29332647 )
2018
32
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. ( 29806961 )
2018
33
Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes. ( 29697766 )
2018
34
Prevalence of Multidrug-Resistant Tuberculosis and Associated Factors in Ethiopia: A Systematic Review. ( 29850257 )
2018
35
Isothermal Point Mutation Detection: Toward a First-Pass Screening Strategy for Multidrug-Resistant Tuberculosis. ( 28766343 )
2017
36
High treatment success rate among multidrug-resistant tuberculosis patients in Myanmar, 2012-2014: a retrospective cohort study. ( 29351672 )
2017
37
Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. ( 28073344 )
2017
38
Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. ( 28847228 )
2017
39
Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. ( 28089216 )
2017
40
Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant tuberculosis in South Africa. ( 28783758 )
2017
41
Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania. ( 28808447 )
2017
42
Lophomonas blattarum co-infection in a patient with multidrug-resistant tuberculosis. ( 28911366 )
2017
43
Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India. ( 28786799 )
2017
44
Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. ( 28804170 )
2017
45
Collaborative public-private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012-2016. ( 29355239 )
2017
46
Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. ( 28775941 )
2017
47
Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. ( 28845791 )
2017
48
Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal. ( 28884143 )
2017
49
Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty? ( 28049180 )
2017
50
Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis. ( 28779436 )
2017

Variations for Multidrug-Resistant Tuberculosis

Expression for Multidrug-Resistant Tuberculosis

Search GEO for disease gene expression data for Multidrug-Resistant Tuberculosis.

Pathways for Multidrug-Resistant Tuberculosis

GO Terms for Multidrug-Resistant Tuberculosis

Cellular components related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 DEFA1 DEFA3 IL10 IL1A INHA TNF

Biological processes related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 IL10 IL1A INHA TNF
2 inflammatory response GO:0006954 9.86 IL10 IL1A SLC11A1 TNF
3 positive regulation of gene expression GO:0010628 9.85 IL1A SLC11A1 TNF VDR
4 immune response GO:0006955 9.77 DEFA1 IL10 IL1A SLC11A1 TNF
5 defense response GO:0006952 9.74 DEFA1 DEFA3 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.69 DEFA1 DEFA3 TNF
7 defense response to Gram-negative bacterium GO:0050829 9.67 DEFA1 DEFA3 SLC11A1
8 negative regulation of mitotic cell cycle GO:0045930 9.62 IL10 TNF
9 defense response to fungus GO:0050832 9.61 DEFA1 DEFA3
10 positive regulation of cytokine production GO:0001819 9.61 SLC11A1 TNF
11 negative regulation of interleukin-6 production GO:0032715 9.6 IL10 TNF
12 innate immune response in mucosa GO:0002227 9.59 DEFA1 DEFA3
13 intracellular estrogen receptor signaling pathway GO:0030520 9.58 DEFA1 DEFA3
14 antimicrobial humoral response GO:0019730 9.58 DEFA1 DEFA3 SLC11A1
15 negative regulation of growth of symbiont in host GO:0044130 9.54 IL10 TNF
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 IL10 TNF
17 membrane disruption in other organism GO:0051673 9.48 DEFA1 DEFA3
18 endothelial cell apoptotic process GO:0072577 9.46 IL10 TNF
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.43 IL10 TNF
20 positive regulation of cytokine secretion GO:0050715 9.43 IL10 IL1A TNF
21 defense response to bacterium GO:0042742 9.35 DEFA1 DEFA3 IL10 SLC11A1 TNF
22 defense response to protozoan GO:0042832 9.33 DEFA1 IL10 SLC11A1
23 receptor biosynthetic process GO:0032800 9.32 IL10 TNF
24 cellular response to lipopolysaccharide GO:0071222 9.02 DEFA1 DEFA3 IL10 TNF VDR
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 IL10 IL1A SLC11A1 TNF VDR

Molecular functions related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL10 IL1A INHA TNF

Sources for Multidrug-Resistant Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....